Franziska Wachter

834 total citations
28 papers, 521 citations indexed

About

Franziska Wachter is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Franziska Wachter has authored 28 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Hematology. Recurrent topics in Franziska Wachter's work include Acute Myeloid Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Cell death mechanisms and regulation (6 papers). Franziska Wachter is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Cell death mechanisms and regulation (6 papers). Franziska Wachter collaborates with scholars based in United States, Germany and Switzerland. Franziska Wachter's co-authors include Loren D. Walensky, Gregory H. Bird, Irmela Jeremias, Harald Ehrhardt, Yana Pikman, Thomas E. Wales, M Grunert, Susan Lee, John R. Engen and Rachel M. Guerra and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Neuron.

In The Last Decade

Franziska Wachter

27 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franziska Wachter United States 13 369 157 70 53 42 28 521
Anne Gardin Switzerland 15 480 1.3× 146 0.9× 37 0.5× 83 1.6× 54 1.3× 25 791
Jie Wen China 13 339 0.9× 204 1.3× 64 0.9× 94 1.8× 23 0.5× 30 665
Prahlad V. Raninga Australia 15 533 1.4× 175 1.1× 79 1.1× 78 1.5× 56 1.3× 25 742
Michael J. Roy Australia 10 460 1.2× 141 0.9× 61 0.9× 23 0.4× 52 1.2× 15 568
Shan‐Liang Sun China 13 311 0.8× 117 0.7× 52 0.7× 67 1.3× 15 0.4× 37 465
Adam J. Stein United States 11 418 1.1× 43 0.3× 69 1.0× 51 1.0× 45 1.1× 13 603
Yusuke Kamada Japan 15 497 1.3× 125 0.8× 28 0.4× 42 0.8× 31 0.7× 23 634
Olaf Witt Germany 14 327 0.9× 109 0.7× 31 0.4× 29 0.5× 15 0.4× 25 523
Vidula Sukhatme United States 8 353 1.0× 190 1.2× 23 0.3× 56 1.1× 22 0.5× 17 751
Masaki Gouda Japan 9 235 0.6× 85 0.5× 37 0.5× 28 0.5× 42 1.0× 11 385

Countries citing papers authored by Franziska Wachter

Since Specialization
Citations

This map shows the geographic impact of Franziska Wachter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franziska Wachter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franziska Wachter more than expected).

Fields of papers citing papers by Franziska Wachter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franziska Wachter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franziska Wachter. The network helps show where Franziska Wachter may publish in the future.

Co-authorship network of co-authors of Franziska Wachter

This figure shows the co-authorship network connecting the top 25 collaborators of Franziska Wachter. A scholar is included among the top collaborators of Franziska Wachter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franziska Wachter. Franziska Wachter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wahlster, Lara, Lucy A. Godley, Jason X. Cheng, et al.. (2025). ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance. Blood. 146(2). 254–259.
3.
Wachter, Franziska, et al.. (2024). Navigating Treatment Options and Communication in Relapsed Pediatric AML. American Society of Clinical Oncology Educational Book. 44(3). e438690–e438690. 1 indexed citations
4.
Wachter, Franziska, Radosław P. Nowak, Scott B. Ficarro, Jarrod A. Marto, & Eric S. Fischer. (2024). Structural characterization of methylation-independent PP2A assembly guides alphafold2Multimer prediction of family-wide PP2A complexes. Journal of Biological Chemistry. 300(5). 107268–107268. 2 indexed citations
5.
Tsai, Harrison, Mark F Sabbagh, Meagan Montesion, et al.. (2024). Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. Modern Pathology. 37(7). 100509–100509. 7 indexed citations
6.
Wachter, Franziska, Kyle Hebert, Yana Pikman, et al.. (2023). Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders. Pediatric Blood & Cancer. 70(9). e30530–e30530. 4 indexed citations
7.
Prockop, Susan E. & Franziska Wachter. (2023). The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia. Best Practice & Research Clinical Haematology. 36(3). 101485–101485. 10 indexed citations
8.
Sarott, Roman C., Inchul You, Yen-Der Li, et al.. (2023). Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive Chemistry. Journal of the American Chemical Society. 145(40). 21937–21944. 30 indexed citations
9.
Wachter, Franziska, Yana Pikman, Jacob R. Bledsoe, et al.. (2023). Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. SHILAP Revista de lepidopterología. 11(11). e8190–e8190. 1 indexed citations
10.
Wachter, Franziska, Hongyuan Luo, David A. Williams, et al.. (2022). Transient neonatal hemolytic anemia due to the novel gamma globin gene mutation HBG2:C.290T>C, p.Leu97Pro (hemoglobin Wareham). Pediatric Blood & Cancer. 70(1). e30067–e30067. 1 indexed citations
11.
Wachter, Franziska, Roberto Chiarle, Neal I. Lindeman, et al.. (2022). Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. Blood Advances. 6(9). 2893–2896. 1 indexed citations
12.
Wachter, Franziska, Alyaa Al‐Ibraheemi, Maria Trissal, et al.. (2021). Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. PEDIATRICS. 148(6). 2 indexed citations
13.
Wachter, Franziska, Susan Lee, James Luccarelli, et al.. (2017). Allosteric sensitization of proapoptotic BAX. Nature Chemical Biology. 13(9). 961–967. 34 indexed citations
14.
Pazyra‐Murphy, Maria F., Yihang Li, Franziska Wachter, et al.. (2017). Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration. Neuron. 96(2). 373–386.e6. 83 indexed citations
15.
Wachter, Franziska, Ann M. Morgan, Marina Godes, et al.. (2016). Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Oncogene. 36(15). 2184–2190. 29 indexed citations
16.
Wales, Thomas E., Thomas P. Garner, Franziska Wachter, et al.. (2015). Inhibition of Pro-Apoptotic BAX by a Noncanonical Interaction Mechanism. Molecular Cell. 57(5). 873–886. 109 indexed citations
17.
Ehrhardt, Harald, et al.. (2013). Activation of DNA damage response by antitumor therapy counteracts the activity of vinca alkaloids.. PubMed. 33(12). 5273–87. 1 indexed citations
18.
Ehrhardt, Harald, Franziska Wachter, M Grunert, & Irmela Jeremias. (2013). Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis. Cell Death and Disease. 4(6). e661–e661. 39 indexed citations
19.
Ehrhardt, Harald, Franziska Wachter, Martina Maurer, Karsten Stahnke, & Irmela Jeremias. (2011). Important Role of Caspase-8 for Chemosensitivity of ALL Cells. Clinical Cancer Research. 17(24). 7605–7613. 21 indexed citations
20.
Ehrhardt, Harald, Christian P. Moritz, Franziska Wachter, et al.. (2011). Optimized anti–tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood. 118(23). 6123–6131. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne Gardin Breakdown of academic impact, for papers by Jie Wen Breakdown of academic impact, for papers by Prahlad V. Raninga Breakdown of academic impact, for papers by Michael J. Roy Breakdown of academic impact, for papers by Shan‐Liang Sun Breakdown of academic impact, for papers by Adam J. Stein Breakdown of academic impact, for papers by Yusuke Kamada Breakdown of academic impact, for papers by Olaf Witt Breakdown of academic impact, for papers by Vidula Sukhatme Breakdown of academic impact, for papers by Masaki Gouda
Rankless by CCL
2026